The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. BioSpecifics Technologies is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? One simple way to answer this question is to take a look at the year-to-date performance of BSTC and the rest of the Medical group's stocks.
BioSpecifics Technologies is one of 756 individual stocks in the Medical sector. Collectively, these companies sit at #4 in the Zacks Sector Rank. The Zacks Sector Rank gauges the strength of our 16 individual sector groups by measuring the average Zacks Rank of the individual stocks within the groups.
The Zacks Rank emphasizes earnings estimates and estimate revisions to find stocks with improving earnings outlooks. This system has a long record of success, and these stocks tend to be on track to beat the market over the next one to three months. BSTC is currently sporting a Zacks Rank of #1 (Strong Buy).
Over the past three months, the Zacks Consensus Estimate for BSTC's full-year earnings has moved 9.09% higher. This means that analyst sentiment is stronger and the stock's earnings outlook is improving.
Based on the latest available data, BSTC has gained about 33.76% so far this year. Meanwhile, the Medical sector has returned an average of 11.82% on a year-to-date basis. As we can see, BioSpecifics Technologies is performing better than its sector in the calendar year.
Looking more specifically, BSTC belongs to the Medical - Drugs industry, which includes 161 individual stocks and currently sits at #78 in the Zacks Industry Rank. On average, this group has gained an average of 6.93% so far this year, meaning that BSTC is performing better in terms of year-to-date returns.
Going forward, investors interested in Medical stocks should continue to pay close attention to BSTC as it looks to continue its solid performance.
Image: Bigstock
Is BioSpecifics Technologies (BSTC) Stock Outpacing Its Medical Peers This Year?
The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. BioSpecifics Technologies is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? One simple way to answer this question is to take a look at the year-to-date performance of BSTC and the rest of the Medical group's stocks.
BioSpecifics Technologies is one of 756 individual stocks in the Medical sector. Collectively, these companies sit at #4 in the Zacks Sector Rank. The Zacks Sector Rank gauges the strength of our 16 individual sector groups by measuring the average Zacks Rank of the individual stocks within the groups.
The Zacks Rank emphasizes earnings estimates and estimate revisions to find stocks with improving earnings outlooks. This system has a long record of success, and these stocks tend to be on track to beat the market over the next one to three months. BSTC is currently sporting a Zacks Rank of #1 (Strong Buy).
Over the past three months, the Zacks Consensus Estimate for BSTC's full-year earnings has moved 9.09% higher. This means that analyst sentiment is stronger and the stock's earnings outlook is improving.
Based on the latest available data, BSTC has gained about 33.76% so far this year. Meanwhile, the Medical sector has returned an average of 11.82% on a year-to-date basis. As we can see, BioSpecifics Technologies is performing better than its sector in the calendar year.
Looking more specifically, BSTC belongs to the Medical - Drugs industry, which includes 161 individual stocks and currently sits at #78 in the Zacks Industry Rank. On average, this group has gained an average of 6.93% so far this year, meaning that BSTC is performing better in terms of year-to-date returns.
Going forward, investors interested in Medical stocks should continue to pay close attention to BSTC as it looks to continue its solid performance.